Cellular Repair & Recovery
BPC-157
Body Protection Compound-157
Body Protection Compound-157
Research context
BPC-157 corresponds to a partial sequence of body protection compound isolated from human gastric juice. The literature examines fibroblast migration assays measuring cell outgrowth rates, and endothelial models measuring VEGFR2 expression and nitric oxide synthase pathway activity. Additional work characterises stability in gastric conditions relative to peptides of comparable length.
Common assays: Scratch-migration assay · Endothelial tube formation · VEGFR2 transcript quantification · Tendon explant outgrowth
Specification
| Designation | Body Protection Compound-157 |
|---|---|
| Full name | Body Protection Compound-157 |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| CAS number | 137525-51-0 |
| Molecular formula | C62H98N16O22 |
| Molecular weight | 1419.53 g/mol |
| Formats | 10 mL Vial · 15 mL Advanced Liquid Peptide Spray |
| Solubility | Bacteriostatic water, sterile water, dilute acetic acid |
| Storage | Lyophilised: −20 °C, protected from light. Reconstituted: 2–8 °C. |
| Regulatory status | Not an approved drug. Removed from FDA 503A Category 2 in April 2026 and recommended for the 503A bulks list by the advisory committee in July 2026. Since 30 October 2026, an HHS interim policy says the agency will not take enforcement action against licensed 503A compounding of it under set conditions. It has not been added to the bulks list. 2026 status by compound → |
| Current lot | BPC10VAS0526 → |
BPC-157 COA: certificates of analysis by lot
4 lots of BPC-157 have a published certificate of analysis from AxisPharm, LLC, an independent laboratory. Each certificate reports the laboratory's results for that lot.
| Lot | Format | Purity (HPLC-UV) | Reported |
|---|---|---|---|
| BPC10VAS0526 | 10 mg Vial | >99.4% | 2026-05-11 |
| BPC10VBG0326 | 10 mg Vial | >99.5% | 2026-03-25 |
| BPC10VAS0126 | 10 mg Vial | >99.5% | 2026-02-20 |
| BPC30N1125 | 30 mg Spray | >99.0% | 2025-11-13 |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Sikirić P, Seiwerth S, Rucman R, et al.Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tractCurrent Pharmaceutical Design · 2011 Find on PubMed ↗
- Chang CH, Tsai WC, Lin MS, et al.The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationJournal of Applied Physiology · 2011 Find on PubMed ↗
- Hsieh MJ, Liu HT, Wang CN, et al.Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulationJournal of Molecular Medicine · 2017 Find on PubMed ↗
Common questions
What is the amino acid sequence of BPC-157?
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — fifteen residues, hence the classification as a pentadecapeptide.
How is BPC-157 purity verified?
RP-HPLC at 214 nm for purity, LC-MS for identity against 1419.53 g/mol. Peptide content by nitrogen determination is reported separately, since net vial weight includes acetate counterion and residual water.
How should BPC-157 be stored?
Lyophilised at −20 °C protected from light; refrigerated at 2–8 °C once reconstituted. Lot-specific stability data appears on the certificate.
Where can I see the BPC-157 certificate of analysis?
Every published BPC-157 lot has its own certificate page on this site, listed under "BPC-157 COA" above. There are 4 published lots; the most recent, lot BPC10VAS0526, was reported on 2026-05-11 at >99.4% purity by HPLC-UV. The certificates are issued by AxisPharm, LLC, an independent laboratory.
Components, blends and pathway
Related compounds
Wolverine
BPC-157 / TB-500
A prepared blend of the two most extensively studied compounds in the repair signalling literature.
KLOW
BPC-157 / TB-500 / GHK-Cu / KPV
A prepared four-component blend combining repair-signalling and cytokine-pathway compounds.
Wolverine Oral
BPC-157 / KPV
A prepared capsule blend combining BPC-157 with the α-MSH C-terminal tripeptide.
TB-500
Thymosin beta-4 fragment
A synthetic fragment corresponding to the actin-binding domain of thymosin beta-4.